Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
A Phase I, single-center, randomized, double-blind, placebo-controlled study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynamics of single-and multiple-ascending
doses of RDX5791 in healthy male and female subjects.